Subcutaneous RYBREVANT(amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer
Responses were rapid and durable, and tumour shrinkage was observed in 82…
Trex Broadens Western U.S. Reach Through Expansion With IWP
Strategic move reinforces Trex’s leadership position and supports ongoing growth in the…
